Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0721
D. Davar, Hong Wang, S. Behr, Aubrey Murano, Sarah Johnson, Amy Rose, Darryn Bampton, K. Dredge, H. Zarour, J. Rhee, L. Villaruz, Y. Najjar, J. Luke
721 Figure 1 Clinical Trial Schema for Phase IIA Study Evaluating Pixatimod and Nivolumab +/Low-dose Cy in MSS CRC, PD1 R/R Melanoma and PD-1 R/R NSCLC http://dx.doi.org/10.1136/jitc-2022-SITC2022.0721 Abstracts J Immunother Cancer 2022;10(Suppl 2):A1–A1595 A753 PR EP RI Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.
721图1 Pixatimod和Nivolumab +/低剂量Cy治疗MSS CRC、PD1 R/R黑色素瘤和PD-1 R/R NSCLC的IIA期临床试验方案http://dx.doi.org/10.1136/jitc-2022-SITC2022.0721 [J] Immunother Cancer 2022;10(增刊2):A1-A1595 A753 PR EP RI癌症免疫治疗杂志(JITC)预印。本预印本的版权持有人为作者/出资人，他们已授予JITC展示预印本的权限。版权所有。未经允许不得重复使用。
{"title":"721 Pixatimod (P) in combination with nivolumab (N) +/- low-dose cyclophosphamide (Cy) in advanced cancers: a phase IIA basket trial","authors":"D. Davar, Hong Wang, S. Behr, Aubrey Murano, Sarah Johnson, Amy Rose, Darryn Bampton, K. Dredge, H. Zarour, J. Rhee, L. Villaruz, Y. Najjar, J. Luke","doi":"10.1136/jitc-2022-sitc2022.0721","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0721","url":null,"abstract":"721 Figure 1 Clinical Trial Schema for Phase IIA Study Evaluating Pixatimod and Nivolumab +/Low-dose Cy in MSS CRC, PD1 R/R Melanoma and PD-1 R/R NSCLC http://dx.doi.org/10.1136/jitc-2022-SITC2022.0721 Abstracts J Immunother Cancer 2022;10(Suppl 2):A1–A1595 A753 PR EP RI Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"158 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116468192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0712
E. Stawiski, Chad Smith, Tyler Borrman, Zheng Pan, S. Mandl, Vinnu Bhardwaj
{"title":"712 Retrospective tumor microenvironment analysis from a personalized neoTCR-T cell therapy clinical trial and its potential applications for off-the-shelf HPV TCRs","authors":"E. Stawiski, Chad Smith, Tyler Borrman, Zheng Pan, S. Mandl, Vinnu Bhardwaj","doi":"10.1136/jitc-2022-sitc2022.0712","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0712","url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121534509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0378
S. Thomas, Harini Kethar, Linh Nguyen, B. Cieniewicz, Alex Arballo, Priya Baichoo, Damoun Torabi, Ankit Bhatta, Daniel M. Corey
{"title":"378 Chimeric engulfment receptor (CER) T cells with a TLR2 domain synergize with an EGFR inhibitor to target NSCLC cells in vitro and demonstrate APC-like function","authors":"S. Thomas, Harini Kethar, Linh Nguyen, B. Cieniewicz, Alex Arballo, Priya Baichoo, Damoun Torabi, Ankit Bhatta, Daniel M. Corey","doi":"10.1136/jitc-2022-sitc2022.0378","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0378","url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"6 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114026162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.1182
Brian Weinert, Tine D. Hannibal, Preeyam S. Patel, E. Martinenaite, M. Chapellier, M. Carretta, A. Alavi, A. Pedersen, M. Al-Hajj
Background Recent clinical results 1 provide a rationale for cancer immunotherapy based on activation of “ anti-regulatory ” T cells. Anti-regulatory T cells recognize antigens expressed by immunosuppressive cells and thereby target pro-inflammatory signals to the tumor microenvironment. 2 TGFB1 promotes immune suppression in diverse cancers. We hypothesize that activating T cells against TGFB1 may allow targeting of pro-inflammatory immune response to TGFB1-expressing tumors while avoiding the toxicities associated with TGFB1 pan-inhib-ition. TGFB1-specific T cells are frequently detected in humans. 3 Vaccination with a TGFB1 peptide ameliorates fibrosis in a model of chronic colitis 4 and enhances the anti-tumor activity of an HPV16 E7-specific vaccine 5 , indicating a therapeutic potential of a TGFB1 vaccine. Here we sought to enhance the specificity anti-TGFB1 immune responses and identify peptides with high TGFB1 selectivity (vs TGFB2/3), thereby mitigating potential off-target toxicities. To understand the TGFB1 landscape in human tumors we performed a mul-tiplexed IHC analysis of TGFB1 expression on tumor cells and the multiplicity of cells in the tumor microenvironment. Methods PBMCs were assayed by ELISPOT to measure responses to peptides from TGFB1, TGFB2, and TGFB3. TGFB1 expression was examined by multiplex immunofluores-cence in a tissue microarray panel of tumor indications with hyperplexed visualization of markers on a single section. Vaccination is evaluated in mouse models expressing TGFb1. Tumor growth monitored, organs and tumor samples collected.
{"title":"1182 Modulating the tumor microenvironment by a targeting TGFB1 with vaccine-induced immune responses","authors":"Brian Weinert, Tine D. Hannibal, Preeyam S. Patel, E. Martinenaite, M. Chapellier, M. Carretta, A. Alavi, A. Pedersen, M. Al-Hajj","doi":"10.1136/jitc-2022-sitc2022.1182","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.1182","url":null,"abstract":"Background Recent clinical results 1 provide a rationale for cancer immunotherapy based on activation of “ anti-regulatory ” T cells. Anti-regulatory T cells recognize antigens expressed by immunosuppressive cells and thereby target pro-inflammatory signals to the tumor microenvironment. 2 TGFB1 promotes immune suppression in diverse cancers. We hypothesize that activating T cells against TGFB1 may allow targeting of pro-inflammatory immune response to TGFB1-expressing tumors while avoiding the toxicities associated with TGFB1 pan-inhib-ition. TGFB1-specific T cells are frequently detected in humans. 3 Vaccination with a TGFB1 peptide ameliorates fibrosis in a model of chronic colitis 4 and enhances the anti-tumor activity of an HPV16 E7-specific vaccine 5 , indicating a therapeutic potential of a TGFB1 vaccine. Here we sought to enhance the specificity anti-TGFB1 immune responses and identify peptides with high TGFB1 selectivity (vs TGFB2/3), thereby mitigating potential off-target toxicities. To understand the TGFB1 landscape in human tumors we performed a mul-tiplexed IHC analysis of TGFB1 expression on tumor cells and the multiplicity of cells in the tumor microenvironment. Methods PBMCs were assayed by ELISPOT to measure responses to peptides from TGFB1, TGFB2, and TGFB3. TGFB1 expression was examined by multiplex immunofluores-cence in a tissue microarray panel of tumor indications with hyperplexed visualization of markers on a single section. Vaccination is evaluated in mouse models expressing TGFb1. Tumor growth monitored, organs and tumor samples collected.","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114862964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0888
Kana Ichikawa, Ammar Adam, H. Wu, D. Lahr, Lang Xu, Brandon Antonakos, Liv Johannessen, S. Bellon, Ryan G. Kruger, Richard C. Centore, M. Hentemann
Background The BAF family of chromatin remodeling com-plexes are critical regulators of chromatin accessibility and gene expression, and BRM and BRG1 (also known as SMARCA2 and SMARCA4), the catalytic subunits of BAF, provide the enzymatic activity required for chromatin remodeling activity. We have previously identified and characterized a series of novel dual inhibitors of the BRM/BRG1 ATPases, and FHD-286, a potent and selective BRM/BRG1 inhibitor, is currently under clinical investigation for the treatment of metastatic uveal melanoma and advanced hematological malig-nancies (NCT04879017 and NCT04891757). BAF chromatin remodeling complex activities are implicated in many immuno-logic responses, and previous studies have shown the involve-ment of PBAF in the regulation of antitumor immunity. 1 Methods Given the recent reports correlating SMARCA4 deficiency and ICI response, 2 we explored the combination of BRM/BRG1 ATPase inhibition and anti-PD-1 antibody in syngeneic mouse models from various lineages and with different sensitivities to checkpoint inhibition. The combination of FHD-286 and anti-PD-1 antibody provided synergistic efficacy and survival benefit compared to anti-PD-1 alone in A20, CT26, and the immunologically bar-ren B16F10 melanoma model. FHD-286 increased MHCI expression on B16F10
{"title":"888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models","authors":"Kana Ichikawa, Ammar Adam, H. Wu, D. Lahr, Lang Xu, Brandon Antonakos, Liv Johannessen, S. Bellon, Ryan G. Kruger, Richard C. Centore, M. Hentemann","doi":"10.1136/jitc-2022-sitc2022.0888","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0888","url":null,"abstract":"Background The BAF family of chromatin remodeling com-plexes are critical regulators of chromatin accessibility and gene expression, and BRM and BRG1 (also known as SMARCA2 and SMARCA4), the catalytic subunits of BAF, provide the enzymatic activity required for chromatin remodeling activity. We have previously identified and characterized a series of novel dual inhibitors of the BRM/BRG1 ATPases, and FHD-286, a potent and selective BRM/BRG1 inhibitor, is currently under clinical investigation for the treatment of metastatic uveal melanoma and advanced hematological malig-nancies (NCT04879017 and NCT04891757). BAF chromatin remodeling complex activities are implicated in many immuno-logic responses, and previous studies have shown the involve-ment of PBAF in the regulation of antitumor immunity. 1 Methods Given the recent reports correlating SMARCA4 deficiency and ICI response, 2 we explored the combination of BRM/BRG1 ATPase inhibition and anti-PD-1 antibody in syngeneic mouse models from various lineages and with different sensitivities to checkpoint inhibition. The combination of FHD-286 and anti-PD-1 antibody provided synergistic efficacy and survival benefit compared to anti-PD-1 alone in A20, CT26, and the immunologically bar-ren B16F10 melanoma model. FHD-286 increased MHCI expression on B16F10","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124028126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.1310
A. McPherson, Mackenzie J. Bender, Catherine M. Phelps, M. Rana, Surya Pandey, Jake H. Shapira, Angela M. Gocher-Demske, S. Mullett, S. Wendell, D. Davar, R. Hinterleitner, D. Vignali, Alok V. Joglekar, H. Zarour, Marlies Meisel
{"title":"1310 Dietary tryptophan catabolite released by intratumoralLactobacillus reuterifacilitates anti-PD-L1 therapy","authors":"A. McPherson, Mackenzie J. Bender, Catherine M. Phelps, M. Rana, Surya Pandey, Jake H. Shapira, Angela M. Gocher-Demske, S. Mullett, S. Wendell, D. Davar, R. Hinterleitner, D. Vignali, Alok V. Joglekar, H. Zarour, Marlies Meisel","doi":"10.1136/jitc-2022-sitc2022.1310","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.1310","url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"111 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124050320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0817
Lauren R. Byrne, Swati Khanna, R. Martin, Caleigh Howard, Lilia A. Rabia, Michaela Sousares, Jay Zhao, J. Majercak, E. Poma, Chris Moore
Background Despite being approved for clinical use over a decade ago, CTLA-4 mAbs remain encumbered by a narrow therapeutic window and relatively severe adverse event (AE) profile. Increasing data support that CTLA-4 mAb efficacy is primarily driven by depletion of CTLA-4+ T regulatory cells (Tregs) in the tumor microenvironment (TME), while AEs have been linked to an overzealous peripheral T cell response mediated by prolonged CTLA-4 blockade. It has been postu-lated that a more selective approach directly targeting TME-associated Treg cell depletion, while reducing peripheral T cell effects, might improve the tolerability of this class of immune checkpoint inhibitors, yet no CTLA-4 targeted mAb has achieved this. MT-8421 is a potent CTLA-4-targeted engineered toxin body (ETB) that can preferentially deplete high CTLA-4 expressing Tregs in the TME while sparing low CTLA-4 expressing peripheral T cells. In addition, MT-8421 was well-tolerated in a non-GLP non-human primate (NHP) study at doses hundreds-fold higher (450ng/mL) than the IC50 on CTLA-4 expressing cells. Here we demonstrate that MT-8421 synergizes with a PD-1 mAb in a Treg/T cell primary cell co-culture to stimulate T cell proliferative responses through direct Treg cell depletion. 1 Results from animal mod-els including a GLP-NHP study will be described. Methods
{"title":"817 Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity","authors":"Lauren R. Byrne, Swati Khanna, R. Martin, Caleigh Howard, Lilia A. Rabia, Michaela Sousares, Jay Zhao, J. Majercak, E. Poma, Chris Moore","doi":"10.1136/jitc-2022-sitc2022.0817","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0817","url":null,"abstract":"Background Despite being approved for clinical use over a decade ago, CTLA-4 mAbs remain encumbered by a narrow therapeutic window and relatively severe adverse event (AE) profile. Increasing data support that CTLA-4 mAb efficacy is primarily driven by depletion of CTLA-4+ T regulatory cells (Tregs) in the tumor microenvironment (TME), while AEs have been linked to an overzealous peripheral T cell response mediated by prolonged CTLA-4 blockade. It has been postu-lated that a more selective approach directly targeting TME-associated Treg cell depletion, while reducing peripheral T cell effects, might improve the tolerability of this class of immune checkpoint inhibitors, yet no CTLA-4 targeted mAb has achieved this. MT-8421 is a potent CTLA-4-targeted engineered toxin body (ETB) that can preferentially deplete high CTLA-4 expressing Tregs in the TME while sparing low CTLA-4 expressing peripheral T cells. In addition, MT-8421 was well-tolerated in a non-GLP non-human primate (NHP) study at doses hundreds-fold higher (450ng/mL) than the IC50 on CTLA-4 expressing cells. Here we demonstrate that MT-8421 synergizes with a PD-1 mAb in a Treg/T cell primary cell co-culture to stimulate T cell proliferative responses through direct Treg cell depletion. 1 Results from animal mod-els including a GLP-NHP study will be described. Methods","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"99 3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126197912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0619
A. Watson, C. Britton-Rivet, S. Stanhope, L. Collins, K. Ranade, A. Benlahrech
{"title":"619 Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma","authors":"A. Watson, C. Britton-Rivet, S. Stanhope, L. Collins, K. Ranade, A. Benlahrech","doi":"10.1136/jitc-2022-sitc2022.0619","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0619","url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126267096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0667
S. Pal, Sreeni Yalamanchili, Huajiang Li, J. Kanodia, R. Clynes, Zequn Tang, B. Garmezy
{"title":"667 A phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb®819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC)","authors":"S. Pal, Sreeni Yalamanchili, Huajiang Li, J. Kanodia, R. Clynes, Zequn Tang, B. Garmezy","doi":"10.1136/jitc-2022-sitc2022.0667","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0667","url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126404075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1136/jitc-2022-sitc2022.0391
D. Cappabianca, M. Bugel, Sarah Caroline Gomes de Lima, Ross Schwartz, Krishanu Saha, C. Capitini
{"title":"391 Development of a GMP-compatible, virus-free CRISPR CAR T cell manufacturing process","authors":"D. Cappabianca, M. Bugel, Sarah Caroline Gomes de Lima, Ross Schwartz, Krishanu Saha, C. Capitini","doi":"10.1136/jitc-2022-sitc2022.0391","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0391","url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126454388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：